Anthem Biosciences was incorporated on June 13, 2006. The company is an innovation-driven, technology-focused Contract Research, Development, and Manufacturing Organization (CRDMO) with fully integrated operations spanning drug discovery, development, and manufacturing. It is one of the few in India with capabilities in New Chemical Entity (NCE) and New Biological Entity (NBE) across these stages
| Bidding Dates |
|---|
| 14 Jul 2025 - 16 Jul 2025 |
| Subscription |
|---|
| 63.86x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹14,040 | 1 | 13 | 26 | 59.6 M | ₹540 - ₹570 | 74.69 % | ₹32163.2 M - ₹33950.0 M | RHP DOC |
Anthem Biosciences IPO SUBSCRIPTION STATUS
16 Jul '25Anthem Biosciences IPO overall subscription rate was 63.86 times the total available shares
Anthem Biosciences IPO retail subscription rate was 5.64 times in the retail segment
Anthem Biosciences IPO non-institutional investor subscription rate was 42.36 times in the non-institutional investor category
Anthem Biosciences IPO Qualified Institutional Bidder subscription rate was 182.65 times the available shares for Qualified Institutional Bidder
Anthem Biosciences IPO Employees subscription rate was 6.6 times in the Employees category
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers | Employees |
|---|---|---|---|---|
| Category Reservation | 35% | 15% | 50% | - |
16 Jul 2025 (Day 3) | 5.64x | 42.36x | 182.65x | 6.6x |
15 Jul 2025 (Day 2) | 2.08x | 9.72x | 0.59x | 2.58x |
14 Jul 2025 (Day 1) | 0.58x | 1.55x | 0.37x | 0.98x |
Anthem Biosciences FINANCIALS
| Period | Net Profit (Rs in crore) | Revenue from Operations (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| FY25 | 450.9 | 1,844.6 | 418.3 | 105.9 | 36.8% |
| FY24 | 367.1 | 1,419.4 | 140.2 | 30.6 | 36.3% |
| FY23 | 385.9 | 1,056.9 | 306.0 | 121.8 | 41.5% |
Anthem Biosciences IPO SUBSCRIPTION STATUS DETAILS
Anthem Biosciences had 59.6 M shares on offer
Anthem Biosciences IPO offer price was in the range ₹540 - ₹570
Anthem Biosciences IPO minimum Investment was ₹14040
Anthem Biosciences IPO issue size was ₹ 32163.2 M - ₹ 33950.0 M
Anthem Biosciences had a minimum lot size of 26 Shares per application
Anthem Biosciences NUMBER OF SHARES ON OFFER
Anthem Biosciences IPO IMPORTANT DATES
| Issue Open Date | 14 Jul 2025 |
| Issue close Date | 16 Jul 2025 |
| Allotment Date | 17 Jul 2025 |
| Refund Date | 18 Jul 2025 |
| Demat Account Credit Date | 18 Jul 2025 |
| Listing Date | 21 Jul 2025 |
| Listing on Exchange(s) | NSE and BSE |
| Anthem Biosciences Allotment Status | Exchange/ Registrar |
Anthem Biosciences IPO subscription opened on 14 Jul 2025, and closed on 16 Jul 2025
IPO allotment for Anthem Biosciences was finalized on Thursday, 17 Jul 2025
IPO listing for Anthem Biosciences was on NSE and BSE on Monday, 21 Jul 2025
Anthem Biosciences IPO LISTING GAINS
| Issue Price (adjusted) | 570.0 |
| Listing Open Price | 723.0 |
| Listing Close Price | 730.4 |
| Listing Gain% | 26.9% |
| Current Gain% | 47.5% |
Anthem Biosciences Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anthem Biosciences Ltd. | 841 | 47231.4 | 82.2 | 5.8 | 23.7 | 19.4 | 17.2 | 2280.1 | 18.1 | 591.8 | 31.1 | 10.2 | 14.1 |
| Sun Pharmaceutical Industries Ltd. | 1945 | 466670.7 | 38.6 | 2.3 | 7.8 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 50.4 | 16.6 |
| Divi's Laboratories Ltd. | 8275 | 219675.3 | 75.1 | 2.8 | 19.6 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4924 | 187293.2 | 85.9 | 9.6 | 11.9 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 57.3 | 8.9 |
| Cipla Ltd. | 1463.8 | 118253.6 | 35.1 | -0.9 | 4.2 | 11.3 | 9.1 | 29044.6 | 2.2 | 3879.2 | -26.4 | 41.7 | -37.5 |
| Zydus Lifesciences Ltd. | 1114.2 | 112114.6 | 22.2 | 2.3 | 4.1 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 50.1 | 9.6 |
Anthem Biosciences INFORMATION ON IPO ISSUE
About Anthem Biosciences
Anthem Biosciences was incorporated on June 13, 2006. The company is an innovation-driven, technology-focused Contract Research, Development, and Manufacturing Organization (CRDMO) with fully integrated operations spanning drug discovery, development, and manufacturing. It is one of the few in India with capabilities in New Chemical Entity (NCE) and New Biological Entity (NBE) across these stages
Object of the Issue
- To carry out the offer for sale of equity shares of face value of Rs 2 each by the selling shareholders aggregating up to Rs 3,395 crore
- Achieve the benefits of listing equity shares on the stock exchanges
Anthem Biosciences - PROMOTERS
| Name |
|---|
| Ajay Bhardwaj |
| Ishaan Bhardwaj |
| Ganesh Sambasivam |
| K Ravindra Chandrappa |
Anthem Biosciences Book Running Lead Manager
JM Financial Limited
Anthem.ipo@jmfl.com
Citigroup Global Markets India Private Limited
anthem.ipo@citi.com
J.P. Morgan India Private Limited
anthem_ipo@jpmorgan.com
Nomura Financial Advisory and Securities (India) Private Limited
anthembioipo@nomura.com
Anthem Biosciences Registrar to the Offer
KFin Technologies Limited
anthem.ipo@kfintech.com
Anthem Biosciences Strengths
Automated manufacturing infrastructure
The company operates two CGMP (current good manufacturing practice)--compliant manufacturing facilities in India (Units I and II) with a combined annual custom synthesis capacity of 270 kL and fermentation capacity of 142 kL. The fermentation capacity is the largest among all assessed Indian CRDMO companies, according to the F&S Report
Tailored business model
The company follows a differentiated business model that caters to the needs of small pharmaceutical and emerging biotech companies, offering integrated services from drug discovery to commercial manufacturing. This model supports these companies in overcoming challenges related to funding, technical expertise, and manufacturing scalability
Innovation focused
The company’s innovation-focused approach allows it to offer a wide range of technologically advanced solutions across various modalities and manufacturing practices. This enables them to stay ahead in the competitive landscape and meet diverse client needs effectively
Anthem Biosciences Risks
Inability to develop or improve technologies
Failure to develop new technologies or improve existing ones may adversely affect the company's competitive position, potentially leading to a material impact on its business, financial condition, and results of operations
Periodic inspections & audits
Failure to obtain required approvals from regulatory authorities and customers in a timely manner could negatively impact the company's business, operations, financial condition, and cash flows
Risk of accidents
The company faces risks of loss due to fire, accidents, and other hazards, as its R&D and manufacturing processes involve flammable and hazardous materials. Any interruptions or delays in manufacturing could impact customer demand and harm business, financial condition, and operations
IPO FAQs
This IPO consists of an offer for sale of up to Rs 3,395.0 crore, of 59,561,404 shares.
The promoters of the company are Ajay Bhardwaj, Ishaan Bhardwaj, Ganesh Sambasivam and K Ravindra Chandrappa.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 540.0 - 570.0.
The IPO application opens on Jul 14, 2025 and closes on Jul 16, 2025.
The minimum lot size for the IPO is 26. The maximum lot size for the IPO is 338.
For all category investors, the minimum application amount for this IPO is Rs. 14,040.0, the maximum value for this IPO is Rs 192,660.0.
This IPO will be allotted on Jul 17, 2025.
The refund will be credited to your account on Jul 18, 2025.
The allotted shares will be credited to your demat on Jul 18, 2025.
Anthem Biosciences Ltd.’s shares listed on the stock exchanges on Jul 21, 2025.